Macitentan and morbidity and mortality in pulmonary arterial hypertension. - Wikidata - awgldk - TriplyDB

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q44343572

about

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension Pulmonary hypertension in the elderly: a different disease?Endothelin The limits of oral therapy in pulmonary arterial hypertension management Medical treatment update on pulmonary arterial hypertension Pulmonary hypertension: diagnostic and therapeutic challenges The molecular targets of approved treatments for pulmonary arterial hypertension Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan Drug treatment of pulmonary hypertension in children Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course Endothelin receptors and their antagonists A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy Recent advances in the management of pulmonary arterial hypertension Treatment-related biomarkers in pulmonary hypertension Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12 The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities Novel biomarkers for risk stratification in pulmonary arterial hypertension Pulmonary Hypertension in Children.Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data.Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease.Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.Update in pulmonary vascular diseases 2013.Identifying "super responders" in pulmonary arterial hypertension.Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.Therapeutic impact of dietary vitamin D supplementation for preventing right ventricular remodeling and improving survival in pulmonary hypertension.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report Are hemodynamics surrogate end points in pulmonary arterial hypertension?Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry.Progress in the diagnosis and management of pulmonary hypertension in children.Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.Macitentan for the treatment of pulmonary arterial hypertension.The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts.Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension.

P2860

Q26747812-7FF528E7-A578-4109-A2F0-E09E6401ABE0 Q26749453-B6C9A6E5-7354-49CA-8218-7FC5A2DA1EBC Q26767156-5D570956-F615-4B0A-8FDF-4F36BE0F4F47 Q26773209-AB704845-78F5-4D28-9415-25BC9C48D3F8 Q26785995-4887AB80-7CC9-4238-B7E9-1CB0350E30C8 Q26796434-2EF60903-93F4-4777-8342-39D250B33A3F Q26798308-19AAC61E-5198-4CB4-B6A0-121F954C58DA Q26851546-B8153EE9-CA59-497A-B8A7-D2A933D6A36E Q26996078-F450BA78-8E03-48D1-A580-26A174F59CA7 Q27023074-D273DE6E-4E97-42FF-8B83-8BB321A70E51 Q27023208-A0BCDB81-3F07-43AB-8816-F6396AFD8358 Q28072562-115E794F-8FE8-4F54-B780-0F0A7DE07314 Q28075707-0963AA9A-5EBD-4826-A14E-1BA095E62FCF Q28081276-767977DF-B0BC-4DCF-8913-FC6B015D154A Q28083099-BA6132F2-1462-4A3A-A0B1-787565A97477 Q28246158-F5CA2ED9-36BC-4B2F-B91A-6A357FEF7179 Q28551385-0CFDF0BA-CCE1-45A9-813A-9AD9D2C9259F Q28596829-78DA29E1-77F8-4B6F-A11B-3AF92A25B17F Q30248871-D8ACEA3E-590A-43B8-B5A2-3926225A16EF Q31108228-C92B5146-B044-4763-A09C-57306DFEE137 Q33580827-AAE5DDD8-0410-4B9A-8841-FF8907AFEF06 Q33589653-A115FEB6-FB3C-4C2B-863D-72B9D85E7A51 Q33608215-2F0C4492-FFA3-4254-B88D-4C033B253C05 Q33673947-2FAB8BB9-D650-4E22-9A63-54B893065BFD Q33732209-4F3AD35F-4A99-442D-AE90-570518CBA979 Q33788452-1B3ED3D4-D9A3-4012-93D6-4C98E8D90B87 Q33788582-2372168B-7CB6-4FD5-82FB-B17383A26678 Q33806102-488920BD-F076-45AD-9327-DF99FF54D072 Q33810499-5EF3FD99-BD93-42B6-8B7B-8BA568CB9409 Q33884093-B24483EF-79AC-4E26-948D-398D7F89FD10 Q33965898-F49E53AD-5335-4FD8-AE26-CD35AC850DB9 Q33965904-912DEE22-60CE-45B7-A03A-1C6C862A50A0 Q34064492-16148E8E-3797-4988-9422-F0EEDBD3BDB8 Q34098418-83B0786A-1834-48F3-B96F-0625ACCAFF21 Q34448350-13C398D2-F89E-476B-984A-C75687C20511 Q34479289-16A04D79-48DA-410C-A61A-F0885AD4FFA9 Q34570893-4B9D4370-E79E-423B-8214-1EE18164EBF3 Q34610092-C0240CF2-0216-422A-BC49-B8D1B057A8AC Q34782476-D15D4B98-5019-4A43-AE8F-B8AF6C40020E Q34993093-3F4FA14E-7A2D-4B4F-87D8-BAFA219326F7

P2860

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q44343572

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

@en

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

@nl

type

label

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

@en

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

@nl

prefLabel

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

@en

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

@nl

P1433

Q44343572-4AB121AB-D2F2-48CF-86AB-1D929D26415E

P1476

Q44343572-3BCB9623-A9F1-478D-B4C7-3A36679BA1D1

P2093

Q44343572-0037D6E9-B263-4630-83A2-DDC2BD546341

Q44343572-1702E9E1-798A-41B4-8B23-347A9F925CEE

Q44343572-2B6E98CD-AE0B-4DB1-851F-026387128B23

Q44343572-33A9865E-376A-4D25-ADFF-75A4FE172963

Q44343572-3D2B4D06-4453-4A46-8CC7-386B88A4D7E9

Q44343572-474E5F87-9D84-4F8D-A502-A23B8C441C5F

Q44343572-550D733B-DD60-4A28-8E71-ABB883C7418B

Q44343572-550D7DD3-60A2-421F-B92E-9E51321616F4

Q44343572-5752616C-EA2D-4573-B687-370D301DC90D

Q44343572-5D9168F4-27D6-48CD-BC0C-33D63667806D

P304

Q44343572-7333A369-C536-48FC-BBE5-325D1FCA0703

P31

Q44343572-98312532-29DD-42E0-B3EA-6D0C55F92896

P356

Q44343572-674BCDA7-DE65-447C-AF8F-606C4902B74E

P407

Q44343572-B39A1B0E-D2AF-48A5-A5D8-2FD93CE7372D

P433

Q44343572-B3986A97-A100-4E6A-804E-2A8361480C82

P478

Q44343572-66A12AB7-C4A2-4794-9A48-AE1C3A47E1B7

P50

Q44343572-73CB8BF5-B09F-4D92-AD98-BAE79B97D48D

Q44343572-8F6C7F1B-1302-4C68-B1B8-DFC6B242A073

Q44343572-DDB1D07C-F808-49B9-865B-728708B47A6B

P577

Q44343572-9238E798-DD30-484F-8A48-37D54DE72B91

P698

Q44343572-5C838321-F9B5-42E1-81F3-4F890BDD0B39

P921

Q44343572-D2F80018-367A-4B3B-A0FE-B15F0D69F22F

P356

P1433

The New England Journal of Medicine

P1476

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

@en

P2093

Adam Torbicki

http://www.w3.org/2001/XMLSchema#string

B K S Sastry

http://www.w3.org/2001/XMLSchema#string

Camilla M Mittelholzer

http://www.w3.org/2001/XMLSchema#string

Franck-Olivier Le Brun

http://www.w3.org/2001/XMLSchema#string

Gérald Simonneau

http://www.w3.org/2001/XMLSchema#string

Hossein-Ardeschir Ghofrani

http://www.w3.org/2001/XMLSchema#string

Igor Adzerikho

http://www.w3.org/2001/XMLSchema#string

Lewis J Rubin

http://www.w3.org/2001/XMLSchema#string

Loïc Perchenet

http://www.w3.org/2001/XMLSchema#string

Marion Delcroix

http://www.w3.org/2001/XMLSchema#string

P304

809-818

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1213917

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23984728

http://www.w3.org/2001/XMLSchema#string

P921